2nd Quarter 2026
Key topics in this quarter’s edition include:
- Tryngolza (olezarsen) for treatment of severe hypertriglyceridemia
- Insulin efsitora alfa for treatment of type 2 diabetes
- Oveporexton for treatment of narcolepsy
- Brepocitinib for treatment of dermatomyositis